Feb 08th 2013 - Edison Investment Research today published a report on quickview entitled "Isa Interest Intensifies". In summary, the report says:
Pivotal isavuconazole data in H213 could reinvigorate investor attention and pave the way for filing in 2014. In addition, progress with the early stage pipeline continues. Although uncertainties remain around ceftobiprole, management’s commitment to partnering rather than conducting further clinical trials is encouraging. The strong cash position reported with 2012 financial results underpins 70% of the current market cap, providing downside protection.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »